Epo Biomarkers Market

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
EPO BIOMARKERS MARKET ANALYSIS

• Epos Biomarkers Market, by Biomarker Type
  (Recombinant Human Erythropoietin, Erythropoietin
  Alfa, Erythropoietin Beta, Erythropoietin Zeta,
  Erythropoietin Theta, and Darbepoietin Alfa), by
  Application (End-stage Renal Disorder, Cancer,
  Rheumatoid Arthritis, AIDS, Myelodysplastic
  Syndrome, Neurology, Hematology, and Others), by
  End User (Diagnostic Centers, Hospitals, and
  Ambulatory Care and Surgical Centers), and by
  Region (North America, Latin America, Europe,
  Asia Pacific, Middle East, and Africa) - Size,
  Share, Outlook, and Opportunity Analysis, 2020 -
  2027

3

• Erythropoietin (Epo) is a glycoprotein hormone
  that consists 165 amino acids with four complex
  carbohydrate chains attached to the peptide at
  four linkage sites. Epo adjusts red blood cell
  production to meet the tissue oxygen demand. Epo
  biomarkers are used for treating cancers and
  associated anemia, AIDS, and mostly in end-stage
  renal disorders (ESRD). There are five different
  type of epo biomarkers.
• Drivers
• The epo biomarkers market is expected to witness
  significant growth over the forecast period,
  owing to increasing launch and adoption of
  erythropoietin alfa in cancer patients who are
  suffering from anemia. For instance, in November
  2018, Pfizer launched epoetin alfa biosimilar
  Retacrit at 33 discounted rate than the
  original drug in the U.S. for treatment of anemia
  caused by chronic kidney disease and
  chemotherapy.

4

• Market Restraints
• A major restraining factor for the epo biomarkers
  market growth is the over-production of red blood
  cells due to over-expression of epo biomarkers,
  which leads to absolute polycythemia and other
  conditions. Overproduction of epo may be an
  adaptive response associated with conditions that
  produce tissue hypoxia such as living at high
  altitude, chronic obstructive pulmonary disease,
  cyanotic heart disease, and sleep apnea.
  According to an article published in Biospace
  Journal in 2015, in the U.S. between 40 and 90
  of cancer patients suffer from chemotherapy-induce
  d anemia. Use of epo in cancer patients that
  suffer from chemotherapy-induced anemia was
  restricted by the Food and Drug Administration
  (FDA) due to increasing adverse events including
  decreased survival and increased risk of tumor
  progression and recurrence

5

• Market Opportunities
• North America is expected to hold a dominant
  position in the epo biomarkers market over the
  forecast period, owing to robust healthcare
  infrastructure and increasing prevalence of
  cancer in the region. According to World Health
  Organizations (WHO) 2018 report, around 609,640
  deaths were recorded due to cancer and around 1.7
  million new cases of cancer were diagnosed in
  2018 in the U.S.
• Asia Pacific is expected to witness significant
  growth in the epo biomarkers market, owing to
  presence of major companies such as 3Sbio Group,
  Biocon Ltd., Genscript, Intas Pharmaceuticals
  Ltd., Kyowa Hakko Kirin Co., Ltd., and Shandong
  Kexing Bioproducts Co. Ltd. Moreover, increasing
  prevalence of AIDS in India, China, Pakistan, and
  Bangladesh is also contributing to epo biomarker
  market growth. For instance, according to the
  UNAIDS Data 2018 for Asia Pacific region, in
  India 2.1 million people are living with HIV AIDS
  at the end of 2017.

6

• Competitive Landscape
• Key players operating in the global epo
  biomarkers market include,  3Sbio Group, Agilent
  Technologies, Inc., Amgen Inc., Bioagilytix Labs,
  Biocon Ltd., Bio-Rad Laboratories, Inc., F.
  Hoffmann-La Roche Ltd., Galenica Ag, Genscript,
  Glaxosmithkline Plc., Intas Pharmaceuticals Ltd.,
  Johnson Johnson, Inc., Kyowa Hakko Kirin Co.,
  Ltd., Teva Pharmaceutical Industries Ltd., Merck
  Kgaa, Myriad Rbm, Novartis Ag, Pacific
  Biomarkers, Pfizer Inc., Shandong Kexing
  Bioproducts Co. Ltd., Siemens Ag, and Thermo
  Fisher Scientific.
• Global Epo Biomarkers Market Taxonomy
• The global epo biomarker market is segmented on
  the basis of biomarker type, application, end
  user, and region.

7

• By Biomarker Type
• Recombinant human erythropoietin
• Erythropoietin alfa
• Erythropoietin beta
• Erythropoietin zeta
• Erythropoietin theta
• Darbepoietin alfa
• By Application
• End-Stage Renal Disorder
• Cancer
• Rheumatoid Arthritis
• AIDS
• Myelodysplastic Syndrome
• Neurology
• Hematology
• Others

8

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Referencehttps//www.coherentmarketinsights.com/o
  ngoing-insight/epo-biomarkers-market-4057

9
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

10
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

11

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/